CD6 attenuates early and late signaling events, setting thresholds for T‐cell activation

Abstract

The T lineage glycoprotein CD6 is generally considered to be a costimulator of T-cell activation. Here, we demonstrate that CD6 significantly reduces early and late T-cell responses upon superantigen stimulation or TCR triggering by Abs. Measuring calcium mobilization in single cells responding to superantigen, we found that human T cells expressing rat CD6 react significantly less well compared with T cells not expressing the exogenous receptor. When the cytoplasmic domain of rat CD6 was removed, calcium responses were recovered, indicating that the inhibitory properties of CD6 are attributable to its cytoplasmic domain. Calcium responses, and also late indicators of T-cell activation such as IL-2 release, were also diminished in TCR-activated Jurkat cells expressing human CD6, compared with CD6-deficient cells or cells expressing a cytoplasmic deletion mutant of human CD6. Similarly, calcium signals triggered by anti-CD3 were enhanced in human T lymphocytes following morpholino-mediated suppression of CD6 expression. Finally, the proliferation of T lymphocytes was increased when the CD6–CD166 interaction was blocked with anti-CD166 Abs, but inhibited when anti-CD6 Abs were used. Our data suggest that CD6 is a signaling attenuator whose expression alone, i.e. in the absence of ligand engagement, is sufficient to restrain signaling in T cells.

Identifying Driver Genes of Breast Cancer by Integrated Analysis of Methylation and Expression Data in Paired Disease-Normal Samples of Patients

“…For an example, tumor suppressor gene RBP1 is a regulator of breast epithelial retinoic acid recepter activity, cell differentiation, growth arrest and cell cycle progression [9], [10], and it was identified as a driver genes with promoter hypermethylation disturbing "cell cycle". As another example, CD6 was identified as a driver genes with promoter hypomethylation, in accordance with previous report that increased expression of CD6 suppresses longer term events such as cytokine secretion and T-cell proliferation [11], which could promoter the initiation of cancer. Secondly, in addition to the known cancer genes collected in the F-census database, some driver genes have been suggested to be cancer genes in previous studies.…”

The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial

“…Thus, while the T cell‐activating properties of CD6 depend upon binding to CD166, its inhibitory effects have been shown to be independent of the interaction with this ligand. Furthermore, ligand‐dependent localization of CD6 at the synapse region is not required for the inhibitory functions, whereas it is required for the T cell‐activating functions of CD6 .…”

Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6

“…Functional studies using mAbs to CD6 have demonstrated its role in T cell activation, proliferation [27]–[30] and in regulating the expression of intracellular phosphoproteins and production of proinflammatory cytokines [31]. Furthermore, CD6 is involved in the maturation of the immunological synapse (IS) by associating at the central supramolecular activation cluster (cSMAC) region [25].…”